Tempus AI, Inc. logo TEM - Tempus AI, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 8
HOLD 5
SELL 0
STRONG
SELL 0
| PRICE TARGET: $75.43 DETAILS
HIGH: $100.00
LOW: $59.00
MEDIAN: $80.00
CONSENSUS: $75.43
UPSIDE: 58.52%

Stock News

Tempus AI: Taking Advantage Of Investor Myopia

Tempus AI: Taking Advantage Of Investor Myopia

Tempus AI is a precision medicine leader leveraging AI and a unique data estate, with significant partnerships and a rapidly growing contract backlog exceeding $1 billion. TEM's recent share price decline and controversy around profitability have compressed valuation, creating an attractive entry point for risk-tolerant investors seeking positive alpha. Data licensing revenues rose nearly 70% last quarter, with foundation models and AI-driven products fueling high-margin growth and reinforcing TEM's competitive moat.

May 22, 2026 05:43 AM • seekingalpha.com
Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic test will be fully integrated into the Tempus platform, providing urologists and oncologists with a digital pathology solution that helps inform personalization of therapy intensity in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The ArteraAI Prosta.

May 21, 2026 04:30 AM • businesswire.com
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration aims to leverage AI, multimodal real-world data and data science techniques to optimize clinical trial designs and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial clinical trial programs. With Lens, Tempus' AI-enabled analytical pl.

May 14, 2026 04:30 AM • businesswire.com
Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”

Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced that its CARE Program (Comprehensive, Assessment, Risk, and Education) has been awarded “Best Overall Health Informatics Solution” in the 10th Annual MedTech Breakthrough Awards. The global program recognizes excellence in digital health and medical technology, selecting CARE from more than 5,000 nominations worldwide. The CA.

May 11, 2026 02:00 AM • businesswire.com
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine

Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine

Tempus AI, Inc. is positioned as a data-driven precision medicine leader, leveraging AI and a vast multi-modal patient database to drive diagnostics and biopharma partnerships. TEM's dual business model—genomic diagnostics and data licensing—creates network effects, with diagnostics feeding a proprietary data moat that underpins high-margin, scalable growth. Despite a 50% share price decline from highs and ongoing unprofitability, TEM's rising revenues, expanding gross margins, and robust contract pipeline support a strong buy rating for long-term investors.

May 08, 2026 09:25 AM • seekingalpha.com
Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $400.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The ag.

May 07, 2026 08:59 PM • businesswire.com
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer, subject to market conditions and other factors, $350.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act.

May 07, 2026 03:11 AM • businesswire.com
Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer's disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer's disease blood-based biomarker testing.

May 06, 2026 04:00 AM • businesswire.com
Tempus Reports First Quarter 2026 Results

Tempus Reports First Quarter 2026 Results

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. Revenue of $348.1 million, up 36.1% year-over-year Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28% MRD volume was ~6,500 tests in Q1 2026, up ~500% year-over-year Data and Applications revenue of $87.0.

May 05, 2026 12:01 PM • businesswire.com
Can Nancy Pelosi’s Favorite AI Stock Hope to Regain Its Momentum?

Can Nancy Pelosi’s Favorite AI Stock Hope to Regain Its Momentum?

Investors are watching Tempus AI (NASDAQ: TEM) ahead of first-quarter results due after the close tomorrow. The stock burst into investor consciousness in January 2025 after Nancy Pelosi disclosed a position, ran past $100, and has since shed nearly half its value. From Pelosi Halo to Show-Me Story Pelosi's market-beating track record has turned her trades... Can Nancy Pelosi's Favorite AI Stock Hope to Regain Its Momentum?

May 04, 2026 10:56 AM • 247wallst.com
Tempus to Host Inaugural Investor Day on May 29, 2026

Tempus to Host Inaugural Investor Day on May 29, 2026

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the company will host an Investor Day on Friday, May 29, 2026. The event will start at 8:00 a.m. CT / 9:00 a.m. ET and will feature Tempus' leadership team, including, Founder and CEO Eric Lefkofsky, Chief Financial Officer Jim Rogers, CEO of Data and Applications Ryan Fukushima, CEO of Diagnostics Tom Schoenherr, and Chief Scientific Offic.

Apr 29, 2026 04:30 AM • businesswire.com

Price Targets